Daiichi Sankyo (OTCMKTS:DSNKY) Co., Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.
Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships. A notable example is its co‑development of the antibody‑drug conjugate trastuzumab deruxtecan (marketed under the name Enhertu in many markets) in collaboration with AstraZeneca, which reflects the company’s emphasis on targeted oncology therapies. Its pipeline spans early discovery through late‑stage clinical trials, with ongoing programs aimed at translating laboratory science into new specialty medicines.
The company operates internationally, serving markets in Japan as well as the Americas, Europe and the broader Asia‑Pacific region through a combination of subsidiaries, alliances and licensing arrangements. Commercial activities include regulatory submissions, product launches and life‑cycle management, while manufacturing and clinical development are supported by regional facilities and partner networks. These global operations enable Daiichi Sankyo to bring approved therapies to patients across multiple geographies and to run multinational clinical trials.
Daiichi Sankyo positions itself as a patient‑centric organization focused on innovation and sustainable growth through scientific advancement and strategic collaborations. Its corporate activities are overseen by an executive management team and board of directors responsible for guiding R&D priorities, commercial strategy and compliance with global regulatory standards.
